| Mr David E Thompson, NP | |
|
40 Baldwin Ave, Lugoff, SC 29078-9406 | |
| (803) 408-3262 | |
| (803) 408-8895 |
| Full Name | Mr David E Thompson |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 17 Years |
| Location | 40 Baldwin Ave, Lugoff, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619121290 | NPI | - | NPPES |
| NP1748 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 3636 (South Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sandhills Medical Foundation, Inc. | 8224949821 | 23 |
News Archive
Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
The Medicines Agency of Sweden, MPA, has authorised Herantis Pharma Plc and Renishaw plc's randomised, placebo-controlled Phase 1-2 clinical study, for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) and Renishaw's chronic drug delivery system, in Parkinson's patients.
In its latest recommendations, the US Multi-Society Task Force on Colorectal Cancer Screening confirms that people at average risk should be screened beginning at age 50, and recommends colonoscopy and fecal immunochemical testing as the "first tier" screening tests for this group.
The harmful effects of being overweight have been underestimated, according to a new study that analyzed body mass index, health and mortality data in around 60,000 parents and their children, to establish how obesity actually influences risk of death.
› Verified 6 days ago
| Entity Name | Sandhills Medical Foundation, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568541597 PECOS PAC ID: 8224949821 Enrollment ID: O20031126000326 |
News Archive
Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
The Medicines Agency of Sweden, MPA, has authorised Herantis Pharma Plc and Renishaw plc's randomised, placebo-controlled Phase 1-2 clinical study, for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) and Renishaw's chronic drug delivery system, in Parkinson's patients.
In its latest recommendations, the US Multi-Society Task Force on Colorectal Cancer Screening confirms that people at average risk should be screened beginning at age 50, and recommends colonoscopy and fecal immunochemical testing as the "first tier" screening tests for this group.
The harmful effects of being overweight have been underestimated, according to a new study that analyzed body mass index, health and mortality data in around 60,000 parents and their children, to establish how obesity actually influences risk of death.
› Verified 6 days ago
| Entity Name | Sandhills Medical Foundation, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922584481 PECOS PAC ID: 8224949821 Enrollment ID: O20200528000475 |
News Archive
Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
The Medicines Agency of Sweden, MPA, has authorised Herantis Pharma Plc and Renishaw plc's randomised, placebo-controlled Phase 1-2 clinical study, for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) and Renishaw's chronic drug delivery system, in Parkinson's patients.
In its latest recommendations, the US Multi-Society Task Force on Colorectal Cancer Screening confirms that people at average risk should be screened beginning at age 50, and recommends colonoscopy and fecal immunochemical testing as the "first tier" screening tests for this group.
The harmful effects of being overweight have been underestimated, according to a new study that analyzed body mass index, health and mortality data in around 60,000 parents and their children, to establish how obesity actually influences risk of death.
› Verified 6 days ago
| Entity Name | Sandhills Medical Foundation, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083228779 PECOS PAC ID: 8224949821 Enrollment ID: O20230104003131 |
News Archive
Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
The Medicines Agency of Sweden, MPA, has authorised Herantis Pharma Plc and Renishaw plc's randomised, placebo-controlled Phase 1-2 clinical study, for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) and Renishaw's chronic drug delivery system, in Parkinson's patients.
In its latest recommendations, the US Multi-Society Task Force on Colorectal Cancer Screening confirms that people at average risk should be screened beginning at age 50, and recommends colonoscopy and fecal immunochemical testing as the "first tier" screening tests for this group.
The harmful effects of being overweight have been underestimated, according to a new study that analyzed body mass index, health and mortality data in around 60,000 parents and their children, to establish how obesity actually influences risk of death.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr David E Thompson, NP 645 S 7th Street, Mcbee, SC 29101 Ph: (843) 335-8291 | Mr David E Thompson, NP 40 Baldwin Ave, Lugoff, SC 29078-9406 Ph: (803) 408-3262 |
News Archive
Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
The Medicines Agency of Sweden, MPA, has authorised Herantis Pharma Plc and Renishaw plc's randomised, placebo-controlled Phase 1-2 clinical study, for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) and Renishaw's chronic drug delivery system, in Parkinson's patients.
In its latest recommendations, the US Multi-Society Task Force on Colorectal Cancer Screening confirms that people at average risk should be screened beginning at age 50, and recommends colonoscopy and fecal immunochemical testing as the "first tier" screening tests for this group.
The harmful effects of being overweight have been underestimated, according to a new study that analyzed body mass index, health and mortality data in around 60,000 parents and their children, to establish how obesity actually influences risk of death.
› Verified 6 days ago
Felicia Denise Harris, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 15 Exchange Dr, Lugoff, SC 29078 Phone: 803-424-2200 Fax: 803-408-8608 | |
Gayla R Ramey, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 16 Duke Dr, Lugoff, SC 29078 Phone: 803-295-0607 | |
Justin M Crawford, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 710 Dewitt Dr, Lugoff, SC 29078 Phone: 803-438-1806 | |
Cathy Porter, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1165 Highway 1 S, Suite 400, Lugoff, SC 29078 Phone: 803-408-3262 Fax: 803-408-8895 | |
Jill S Sheorn, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 116 Standard Warehouse Rd, Lugoff, SC 29078 Phone: 803-438-6023 Fax: 803-438-3671 | |
Ayzia Taylor, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 40 Baldwin Ave, Lugoff, SC 29078 Phone: 803-408-3262 | |
Anne B Blake, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 710 Dewitt Dr, Lugoff, SC 29078 Phone: 803-438-7566 Fax: 803-438-4371 |